ReviewOpen forum infectious diseases2022
Olfactomedin 4 Is a Biomarker for the Severity of Infectious Diseases.
Review in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis.Nature communications · 2026Article
- Olfactomedin-4Infection and immunity · 2026Article
- Genetic correlation-guided mega-analysis of DO mice provides mechanistic insight and candidate genes for age-related pathologies.PLoS genetics · 2026Article
- Role of Nod-like Receptors inMicroorganisms · 2026Review
- Article
- Transcriptomic profile of microglia following inflammation-sensitized hypoxic-ischemic brain injury in neonatal rats suggests strong contribution to neutrophil chemotaxis and activation.Journal of neuroinflammation · 2025Article
- Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer's Disease.Molecular neurobiology · 2025Article
- Biomarker Profile in Peripheral Blood Cells Related to Alzheimer's Disease.Molecular neurobiology · 2025Article
- Gene Expression Differences Based on Low Total 25(OH)D and Low VDBP Status with a Preterm Birth.International journal of molecular sciences · 2025Article
- A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia.iScience · 2025Article
- Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia.The Journal of infectious diseases · 2025Article
- Elucidation of neutrophils-mediated effect of MMP-2 on lung epithelial cells; implications for acute respiratory distress syndrome and severe dengue pathogenesis.Frontiers in cellular and infection microbiology · 2025Article
- Proteomics of plasma-derived extracellular vesicles from human patients identifies biomarkers for monitoring visceral leishmaniasis therapy.Frontiers in immunology · 2025Article
- Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.Nature communications · 2024Article
- γδ T Cells Mediate Protection against Neutrophil-associated Lung Inflammation in Pulmonary Melioidosis.American journal of respiratory cell and molecular biology · 2024Article
- Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models.Nature cardiovascular research · 2024Article
- Metabolomics and Multi-Omics Determination of Potential Plasma Biomarkers in PRV-1-Infected Atlantic Salmon.Metabolites · 2024Article
- LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study.Translational psychiatry · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers of infectious diseases are essential tools for patient monitoring, diagnostics, and prognostics. Here we review recent advances in our understanding of olfactomedin 4 (OLFM4) in neutrophil biology and of OLFM4 as a new biomarker for certain infectious diseases. OLFM4 is a neutrophil-specific granule protein that is expressed in a subset of human and mouse neutrophils. OLFM4 expression is upregulated in many viral and bacterial infections, as well as in malaria. OLFM4 appears to play an important role in regulating host innate immunity against bacterial infection. Further, higher expression of OLFM4 is associated with severity of disease for dengue virus, respiratory syncytial virus, and malaria infections. In addition, higher expression of OLFM4 or a higher percentage of OLFM4 + neutrophils is associated with poorer outcomes in septic patients. OLFM4 is a promising biomarker and potential therapeutic target in certain infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.